دورية أكاديمية
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses.
العنوان: | Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. |
---|---|
المؤلفون: | Bayerl F; Institute of Molecular Immunology, School of Medicine, Technical University of Munich, Munich, Germany., Meiser P; Institute of Molecular Immunology, School of Medicine, Technical University of Munich, Munich, Germany., Donakonda S; Institute of Molecular Immunology, School of Medicine, Technical University of Munich, Munich, Germany; German Center for Infection Research, Munich, Germany., Hirschberger A; Institute of Molecular Immunology, School of Medicine, Technical University of Munich, Munich, Germany., Lacher SB; Institute of Molecular Immunology, School of Medicine, Technical University of Munich, Munich, Germany., Pedde AM; Institute of Molecular Immunology, School of Medicine, Technical University of Munich, Munich, Germany., Hermann CD; Institute of Experimental Oncology, School of Medicine, Technical University of Munich, Munich, Germany., Elewaut A; Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria., Knolle M; Institute for Artificial Intelligence in Medicine & Healthcare, School of Medicine, Technical University of Munich, Munich, Germany., Ramsauer L; Institute of Molecular Immunology, School of Medicine, Technical University of Munich, Munich, Germany., Rudolph TJ; Institute of Molecular Immunology, School of Medicine, Technical University of Munich, Munich, Germany., Grassmann S; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine, Technical University of Munich, Munich, Germany., Öllinger R; Institute of Molecular Oncology and Functional Genomics, School of Medicine, Technical University of Munich, Munich, Germany., Kirchhammer N; Cancer Immunology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland., Trefny M; Cancer Immunology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland., Anton M; Institute of Molecular Immunology, School of Medicine, Technical University of Munich, Munich, Germany., Wohlleber D; Institute of Molecular Immunology, School of Medicine, Technical University of Munich, Munich, Germany., Höchst B; Institute of Molecular Immunology, School of Medicine, Technical University of Munich, Munich, Germany., Zaremba A; Department for Dermatology, University Hospital Essen, Essen, Germany., Krüger A; Institute of Experimental Oncology, School of Medicine, Technical University of Munich, Munich, Germany., Rad R; Institute of Molecular Oncology and Functional Genomics, School of Medicine, Technical University of Munich, Munich, Germany., Obenauf AC; Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria., Schadendorf D; Department for Dermatology, University Hospital Essen, Essen, Germany., Zippelius A; Cancer Immunology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland., Buchholz VR; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine, Technical University of Munich, Munich, Germany., Schraml BU; Walter-Brendel Center for Experimental Medicine, LMU Munich, Planegg-Martinsried, Germany; Biomedical Center, Institute for Cardiovascular Physiology and Pathophysiology, LMU Munich, Planegg-Martinsried, Germany., Böttcher JP; Institute of Molecular Immunology, School of Medicine, Technical University of Munich, Munich, Germany. Electronic address: j.boettcher@tum.de. |
المصدر: | Immunity [Immunity] 2023 Jun 13; Vol. 56 (6), pp. 1341-1358.e11. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 9432918 Publication Model: Print Cited Medium: Internet ISSN: 1097-4180 (Electronic) Linking ISSN: 10747613 NLM ISO Abbreviation: Immunity Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Cambridge, MA : Cell Press Original Publication: Cambridge, Mass. : Cell Press, c1994- |
مواضيع طبية MeSH: | Dinoprostone* , Neoplasms*, Humans ; Antibodies ; CD8-Positive T-Lymphocytes ; Dendritic Cells ; Receptors, Prostaglandin E |
مستخلص: | Type 1 conventional dendritic cells (cDC1s) are critical for anti-cancer immunity. Protective anti-cancer immunity is thought to require cDC1s to sustain T cell responses within tumors, but it is poorly understood how this function is regulated and whether its subversion contributes to immune evasion. Here, we show that tumor-derived prostaglandin E2 (PGE Competing Interests: Declaration of interests The authors declare that they have no competing interests. (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.) |
التعليقات: | Comment in: Immunity. 2023 Jun 13;56(6):1165-1167. (PMID: 37315532) |
فهرسة مساهمة: | Keywords: T cells; cancer immunotherapy; dendritic cells; immune evasion; prostaglandin E2; tumor microenvironment |
المشرفين على المادة: | K7Q1JQR04M (Dinoprostone) 0 (Antibodies) 0 (Receptors, Prostaglandin E) |
تواريخ الأحداث: | Date Created: 20230614 Date Completed: 20230616 Latest Revision: 20230619 |
رمز التحديث: | 20240628 |
DOI: | 10.1016/j.immuni.2023.05.011 |
PMID: | 37315536 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1097-4180 |
---|---|
DOI: | 10.1016/j.immuni.2023.05.011 |